First Time Loading...

Incyte Corp
NASDAQ:INCY

Watchlist Manager
Incyte Corp Logo
Incyte Corp
NASDAQ:INCY
Watchlist
Price: 57.79 USD 0.86% Market Closed
Updated: Jun 1, 2024

Incyte Corp
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Incyte Corp
Accounts Receivables Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Incyte Corp
NASDAQ:INCY
Accounts Receivables
$745.5m
CAGR 3-Years
23%
CAGR 5-Years
25%
CAGR 10-Years
32%
Abbvie Inc
NYSE:ABBV
Accounts Receivables
$11.9B
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Receivables
$4.7B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
4%
Amgen Inc
NASDAQ:AMGN
Accounts Receivables
$6.8B
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Receivables
$1.8B
CAGR 3-Years
22%
CAGR 5-Years
33%
CAGR 10-Years
40%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Receivables
$5.2B
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
17%

See Also

What is Incyte Corp's Accounts Receivables?
Accounts Receivables
745.5m USD

Based on the financial report for Mar 31, 2024, Incyte Corp's Accounts Receivables amounts to 745.5m USD.

What is Incyte Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
32%

Over the last year, the Accounts Receivables growth was 20%. The average annual Accounts Receivables growth rates for Incyte Corp have been 23% over the past three years , 25% over the past five years , and 32% over the past ten years .